NBTX ▲ +1.1% - Nanobiotix S.A. $NBTX - NANOBIOTIX Announces Final Data from Phase 1 Study Evaluating JNJ-1900 (NBTXR3) With Immune Checkpoint Inhibitors as a 2L+ Therapy in Anti-PD-1-Resistant Primary Cutaneous Melanoma 24-OCT-2026 07:00 AM ET